論文・総説 - 田中　一

61. Yamamoto S, Fukushima H, Fukuda S, Uehara S, Yasuda Y, Tanaka H, Yoshida S, Yokoyama M, Matsuoka Y, Fujii Y. Early cancer cachexia phenotype predicts survival of advanced urothelial cancer patients treated with pembrolizumab Asia Pac J Clin Oncol (IF: 2.6; Q4). 2022.08;

62. Toide M, Saito K, Yasuda Y, Tanaka H, Fukuda S, Patil D, Cotta BH, Patel SH, Master VA, Derweesh IH, Fujii Y.. Prognostic Significance of C-reactive Protein in Patients With Non-metastatic Papillary Renal Cell Carcinoma: Results from the INternational Marker Consortium for Renal Cancer (INMARC) Cohort. Clin Genitourin Cancer. . 2022.08;

63. Yamamoto S, Fukushima H, Fukuda S, Uehara S, Yasuda Y, Tanaka H, Yoshida S, Yokoyama M, Matsuoka Y, Fujii Y. Early cancer cachexia phenotype predicts survival of advanced urothelial cancer patients treated with pembrolizumab. Asia-Pacific journal of clinical oncology. 2022.08; 18 (4): 410-418. ( PubMed, DOI )

64. Toide M, Saito K, Yasuda Y, Tanaka H, Fukuda S, Patil D, Cotta BH, Patel SH, Master VA, Derweesh IH, Fujii Y. Prognostic Significance of C-reactive Protein in Patients With Non-metastatic Papillary Renal Cell Carcinoma: Results from the INternational Marker Consortium for Renal Cancer (INMARC) Cohort. Clinical genitourinary cancer. 2022.08; 20 (4): e276-e282. ( PubMed, DOI )

65. Tanaka Hajime, Fujii Yasuhisa. 「進行性腎細胞癌の一次治療としての複合癌免疫療法の包括的評価」に対するエディトリアルコメント(Editorial Comment to Comprehensive assessments of immuno-oncology drug-based combination therapies as first-line treatment for advanced renal cell carcinoma) International Journal of Urology. 2022.08; 29 (8): 822-823. ( 医中誌 )

66. Tanaka H, Fujii Y. Editorial Comment to Comprehensive assessments of immuno-oncology drug-based combination therapies as first-line treatment for advanced renal cell carcinoma. International journal of urology : official journal of the Japanese Urological Association. 2022.08; 29 (8): 822-823. ( PubMed, DOI )

67. Tanaka H, Fujii Y. Editorial Comment to Surgical and focal treatment for metastatic renal cell carcinoma: A literature review. Int J Urol. 2022.06; 29 (6): 501-502.

68. Matsumoto S, Arita Y, Yoshida S, Fukushima H, Kimura K, Yamada I, Tanaka H, Yagi F, Yokoyama M, Matsuoka Y, Oya M, Tateishi U, Jinzaki M, Fujii Y. Utility of radiomics features of diffusion-weighted magnetic resonance imaging for differentiation of fat-poor angiomyolipoma from clear cell renal cell carcinoma: model development and external validation Abdom Radiol (NY) (IF: 3.04; Q2). 2022.06;

69. Tanaka H, Fujii Y. Editorial Comment to Surgical and focal treatment for metastatic renal cell carcinoma: A literature review. International journal of urology : official journal of the Japanese Urological Association. 2022.06; 29 (6): 501-502. ( PubMed, DOI )

70. Tanaka Hajime, Fujii Yasuhisa. 「転移性腎細胞癌に対する外科的局所治療　文献レビュー」に対するエディトリアルコメント(Editorial Comment to Surgical and focal treatment for metastatic renal cell carcinoma: A literature review) International Journal of Urology. 2022.06; 29 (6): 501-502. ( 医中誌 )

71. Matsumoto S, Arita Y, Yoshida S, Fukushima H, Kimura K, Yamada I, Tanaka H, Yagi F, Yokoyama M, Matsuoka Y, Oya M, Tateishi U, Jinzaki M, Fujii Y. Utility of radiomics features of diffusion-weighted magnetic resonance imaging for differentiation of fat-poor angiomyolipoma from clear cell renal cell carcinoma: model development and external validation. Abdominal radiology (New York). 2022.06; 47 (6): 2178-2186. ( PubMed, DOI )

72. Nityam Rathi, Diego A Palacios, Emily Abramczyk, Hajime Tanaka, Yunlin Ye, Jianbo Li, Yosuke Yasuda, Robert Abouassaly, Mohamed Eltemamy, Alvin Wee, Christopher Weight, Steven C Campbell. Predicting GFR after radical nephrectomy: the importance of split renal function. World J Urol. 2022.04; 40 (4): 1011-1018. ( PubMed, DOI )

73. Matsuoka Y, Uehara S, Toda K, Fukushima H, Tanaka H, Yoshida S, Yokoyama M, Yoshimura R, Kihara K, Fujii Y. Focal brachytherapy for localized prostate cancer: 5.7-year clinical outcomes and a pair-matched study with radical prostatectomy Urol Oncol (IF: 3.5; Q3). 2022.04;

74. Matsuoka Y, Uehara S, Toda K, Fukushima H, Tanaka H, Yoshida S, Yokoyama M, Yoshimura R, Kihara K, Fujii Y. Focal brachytherapy for localized prostate cancer: 5.7-year clinical outcomes and a pair-matched study with radical prostatectomy. Urologic oncology. 2022.04; 40 (4): 161.e15-161.e23. ( PubMed, DOI )

75. Uchida Y, Yoshida S, Arita Y, Shimoda H, Kimura K, Yamada I, Tanaka H, Yokoyama M, Matsuoka Y, Jinzaki M, Fujii Y. Apparent Diffusion Coefficient Map-Based Texture Analysis for the Differentiation of Chromophobe Renal Cell Carcinoma from Renal Oncocytoma Diagnostics (Basel) (IF: 5.25; Q2). 2022.03;

76. Uchida Y, Yoshida S, Arita Y, Shimoda H, Kimura K, Yamada I, Tanaka H, Yokoyama M, Matsuoka Y, Jinzaki M, Fujii Y. Apparent Diffusion Coefficient Map-Based Texture Analysis for the Differentiation of Chromophobe Renal Cell Carcinoma from Renal Oncocytoma. Diagnostics (Basel, Switzerland). 2022.03; 12 (4): ( PubMed, DOI )

77. Nguyen MV, Walia A, Saidian A, Puri D, Meagher MF, Hakimi K, Tanaka H, Patil D, Yasuda Y, Saito K, Dhanji S, Cerrato C, Narasimhan R, Perry J, Master V, Fujii Y, Derweesh IH. Impact of worsening surgically induced chronic kidney disease (CKD-S) in preoperative CKD-naïve patients on survival in renal cell carcinoma BJU Int. 2022.02; 131 (2): 219-226.

78. Kimura K, Yoshida S, Tsuchiya J, Yamada I, Tanaka H, Yokoyama M, Matsuoka Y, Yoshimura R, Tateishi U, Fujii Y. Usefulness of texture features of apparent diffusion coefficient maps in predicting chemoradiotherapy response in muscle-invasive bladder cancer Eur Radiol (IF: 5.32; Q1). 2022.02;

79. Yoshida S, Takahara T, Arita Y, Toda K, Kimura K, Tanaka H, Yokoyama M, Matsuoka Y, Yoshimura R, Fujii Y. Impact of Progressive Site-Directed Therapy in Oligometastatic Castration-Resistant Prostate Cancer on Subsequent Treatment Response 2022.01;

80. Kimura K, Yoshida S, Tsuchiya J, Yamada I, Tanaka H, Yokoyama M, Matsuoka Y, Yoshimura R, Tateishi U, Fujii Y. Usefulness of texture features of apparent diffusion coefficient maps in predicting chemoradiotherapy response in muscle-invasive bladder cancer. European radiology. 2022.01; 32 (1): 671-679. ( PubMed, DOI )